RapidPulse Secures $48 Million in Series B Funding
RapidPulse, a Miami-based medical technology company, has successfully closed a $48 million Series B funding round. The company is focused on developing innovative treatments and technologies for acute ischemic stroke, offering solutions for both patients and healthcare providers through clinical trials and advanced medical devices.
Investment Details
The Series B round was co-led by Medtronic, TechWald Next S.p.A., and S3 Ventures. Other investors participating in the round included SBI Investment Company Ltd., Florida Opportunity Fund, Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital.
Strategic Use of Funds
The newly acquired funds will primarily be used to support the completion of RapidPulse's ongoing Investigational Device Exemption study, known as the TURBO study. This study focuses on the use of pulsed aspiration technology for treating brain occlusions in stroke patients. Additionally, the funding will aid in the further development of RapidPulse's proprietary technology platform, which includes a comprehensive line of catheter sizes.
Leadership Insights
Sean McBrayer, CEO of RapidPulse, expressed his optimism about the funding, stating: "This financing enables us to complete the TURBO study, expand clinical experience across leading stroke centers, and data permitting, seek FDA approval for the RapidPulse system." McBrayer also highlighted the significance of having Medtronic as a co-lead investor, reflecting the growing recognition of the potential impact of their approach to stroke treatment.
Future Prospects
With the backing of prominent investors and the completion of the TURBO study on the horizon, RapidPulse is well-positioned to advance its stroke treatment technology. The company's focus on expanding its clinical trials and seeking regulatory approval could potentially lead to significant improvements in how acute ischemic strokes are treated, ultimately benefiting patients and healthcare providers alike.
For more information on RapidPulse and their innovative stroke treatment technologies, visit their website.